Mar 24, 2022 5:10pm EDT Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call
Feb 23, 2022 8:31am EST Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference
Feb 08, 2022 4:01pm EST Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
Jan 31, 2022 4:01pm EST Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
Jan 10, 2022 8:00am EST Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid
Jan 05, 2022 4:05pm EST Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference
Jan 04, 2022 8:00am EST Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Dec 15, 2021 4:05pm EST Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection